ClinicalTrials.gg
RecruitingNCT07643610BEAT-SHOCKUpdated Jun 11, 2026

BEAT-SHOCK Registry

An observational study in Cardiogenic Shock, Myocardial Infarction (MI) and Fulminant Myocarditis, sponsored by University Hospital, Basel, Switzerland. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by University Hospital, Basel, Switzerland · Observational

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
8,000
Ages
18 Years and older
Sex
All
01

Study summary

This regulation defines the purpose, the operational processes, and the organization of the registry BEAT-SHOCK (Basel Evaluation of Acute Therapy in cardiogenic SHOCK). It describes the requirements for collecting, storing, processing, managing and sharing health-related registry data.

02

Conditions studied

  • Cardiogenic Shock
  • Myocardial Infarction (MI)
  • Fulminant Myocarditis
  • Acute Decompensated Heart Failure
  • Severe Valvular Disease
  • Post-cardiotomy
  • Perioperative Cardiogenic Shock

Keywords

  • cardiogenic shock
  • Myocardial infarction (MI)
  • Fulminant myocarditis
  • Acute decompensated heart failure
  • Severe valvular disease
  • Post-cardiotomy or perioperative cardiogenic shock
  • wide range of cardiogenic shock etiologies
03

In context

Shock, Cardiogenic

297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.

This study's planned enrollment of 8,000 is above the median of 200 across 156 observational studies indexed under Shock, Cardiogenic.

Browse Shock, Cardiogenic studies →

Lead sponsor

University Hospital, Basel, Switzerland is the lead sponsor of 990 studies on the registry; 189 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients who are treated at the University Hospital Basel and are diagnosed with cardiogenic shock, irrespective of underlying etiology or therapeutic strategy. The registry includes a wide range of cardiogenic shock etiologies, including:

  • Myocardial infarction (MI)
  • Fulminant myocarditis
  • Acute decompensated heart failure
  • Severe valvular disease
  • Post-cardiotomy or perioperative cardiogenic shock

Eligibility criteria

  • Patients admitted with cardiogenic shock to the University hospital Basel (diagnosis at the time of admission) or development of cardiogenic shock during the hospital stay
  • Age ≥18 years
  • Provision of written ICF
  • Clinical diagnosis of cardiogenic shock.
  • impaired organ perfusion due to primary cardiac dysfunction,
  • persistent systolic blood pressure (SBP) \<90 mmHg for ≥30 minutes, or the need for vasopressors, inotropes, or mechanical circulatory support (MCS) to maintain adequate perfusion and
  • evidence of systemic hypoperfusion with arterial lactate ≥2 mmol/L or venous lactate ≥3 mmol/l and ≥1 of the following:
  • Cold or clammy extremities
  • Altered mental status
  • Reduced urine output
  • Signs of volume overload or congestion (on clinical exam, imaging, or invasive monitoring)
  • Patients with normotensive cardiogenic shock (SBP ≥90 mmHg without vasopressors or MCS) may also be included if clear signs of hypoperfusion (arterial lactate ≥2 mmol/L or venous lactate ≥3 mmol/l) and cardiac dysfunction are present and alternative causes are excluded

Exclusion criteria:

  • Age \<18 years
  • Refusal to provide by the patient or their legally authorized representative
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
8,000 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Interventions

  • Otherno internvention

    This is a health data registry.

06

What researchers measure

Primary outcomes

  1. In-Hospital all-cause mortality occurring before discharge from the participating study centre

    In-hospital all-cause mortality is defined as death occurring before discharge from the participating study centre. Deaths occurring after transfer to an external hospital are not counted as in-hospital deaths, but are captured through follow-up for 30-day and 90-day mortality.

    Time frame: 10 years

Secondary outcomes

  1. 30-day and 90-day all-cause Mortality

    30-day and 90-day all-cause mortality occuring after discharge from the participating study centre.

    Time frame: 30, 90 days

  2. Need for organ support at any time during hospitalization

    The need for organ support at any time during hospitalization (including renal replacement therapy, mechanical circulation support irrespective of type, and vasoactive or inotropic therapy)

    Time frame: 30, 60, 360 days

  3. Acute kidney injury (AKI) within 36 hours after index diagnosis of cardiogenic shock/index presentation

    Occurence of AKI (defined as an increase in serum creatinine of at least 26 µmol/L (0.3 mg/dL)

    Time frame: Within 36 hours after index diagnosis of cardiogenic shock/ index presentation.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Not necessary, only data registry.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Oct 2035, 120 months after the start.

Of 79 non-industry observational studies under Shock, Cardiogenic, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 19. This study's planned 120 months is above that.

Counting every sponsor, half of 85 studies reached it within 45 months; a quarter within 24.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2026
First posted
Jun 11, 2026
StartActual
Oct 1, 2025
Primary completionEst.
Oct 1, 2035
CompletionEst.
Oct 1, 2035
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07643610
Responsible party
Sponsor
First posted
Jun 11, 2026
Start date
Oct 1, 2025
Primary completion
Oct 1, 2035 (estimated)
Completion
Oct 1, 2035 (estimated)
Last update
Jun 11, 2026

Study contacts

Jasper Boeddinghaus, PD Dr. med.
Contact
jasper.boeddinghaus@usb.ch
0041613287897
Gregor Leibundgut, Prof. Dr.
Contact
gregor.leibundgut@usb.ch
0041613287897

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion